LI
LAB icon

Leap Investments’s Standard BioTools LAB Stock Holding History

Leap Investments’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$290K Buy
+72,200
New +$251K 0.19% 214
2019
Q4 		– Sell
-61,252
Closed -$284K – 503
2019
Q3 		$284K Buy
+61,252
New +$482K 0.14% 239

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

Leap Investments's LAB Position: Q2 2020 in Review

Leap Investments opened a new position in Standard BioTools (LAB) in Q2 2020: 72,200 shares worth $290K. The stake represents 0.19% of the portfolio and ranks #214 among its holdings. This is a return to the name: Leap Investments previously reported a position in LAB as recently as Q3 2019.

Leap Investments first reported a position in LAB in Q3 2019 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold LAB as of Q2 2020.

  • Leap Investments held 72,200 shares of Standard BioTools worth $290K as of Q2 2020.
  • Standard BioTools was a new Leap Investments position in Q2 2020.
  • Standard BioTools made up 0.19% of Leap Investments's portfolio in Q2 2020, its #214 holding.
  • Leap Investments first reported a position in Standard BioTools in Q3 2019 and has held it in 2 quarters since.
  • 112 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.